

phosphatidyl glycerol (PG); and  
an admixture of DPPC and PG in a weight ratio of  
about 3:1.

15. (Amended) The pulmonary surfactant of claim 13 [8] further comprising palmitic acid, wherein said phospholipid comprises about 50-90 weight percent and said palmitic acid comprises the remaining 10-50 weight percent of said surfactant.

26. (Amended) A [The] pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula KLLLLKLLLLKLLLLKLLLLK <sup>(SEQ ID NO: 1)</sup> said polypeptide, thereby forming a pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone, [of claim 25, wherein] said phospholipid [is] being present in the range of about 50-100 weight percent, in a polypeptide:phospholipid weight ratio in the range of about 1:7 to about 1:1,000.

27. (Amended) The pulmonary surfactant of claim 26 [25], wherein said phospholipid is selected from the group consisting of:

1,2-dipalmitoyl-sn-glycero-3-phosphocholine

(dipalmitoylphosphatidylcholine, DPPC);

phosphatidyl glycerol (PG); and

an admixture of DPPC and PG in a weight ratio of  
about 3:1.

28. (Amended) The pulmonary surfactant of claim 26 [25], further comprising palmitic acid, wherein said phospholipid comprises about 50-90 weight percent and said palmitic acid comprises the remaining 10-50 weight percent of said surfactant.

37. (Amended) A [The] method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a polypeptide

including at least ten amino acid residues and no more than about 60 amino acid residues thereby forming a pulmonary surfactant having a surfactant activity greater than the surfactant activity of phospholipid alone. [claim 34, wherein] said phospholipid [is]being selected from the group consisting of:

1,2-dipalmitoyl-sn-glycero-3-phosphocholine  
(dipalmitoylphosphatidylcholine, DPPC);  
phosphatidyl glycerol (PG); and

an admixture of DPPC and PG in a weight ratio of about 3:1.

38. (Amended) The method of claim 37 [34], wherein said surfactant further comprises palmitic acid, and wherein said phospholipid comprises about 50-90 weight percent and said palmitic acid comprises the remaining 10-50 weight percent of the lipid portion of said surfactant.

04  
~~440~~. (Amended) A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula KLLLLKLLLLKLLLLKLLLLK <sup>(SEQ ID NO:1)</sup> said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone. [The method of claim 39, wherein] said phospholipid [is]being present in the range of about 50-100 weight percent, in a polypeptide:phospholipid weight ratio in the range of about 1:7 to about 1:1,000, or in an amount such that it may be administered in a range of about 50 mg/kg to about 500 mg/kg per dose.

~~541~~. (Amended) The method of claim ~~40~~ <sup>4</sup> [39,] wherein said phospholipid is selected from the group consisting of:

1,2-dipalmitoyl-sn-glycero-3-phosphocholine  
(dipalmitoylphosphatidylcholine, DPPC);